Vertex Pharmaceuticals Incorporated has filed a definitive proxy statement with the United States Securities and Exchange Commission (SEC). This filing is in accordance with Section 14(a) of the Securities Exchange Act of 1934. The proxy statement is a key document that is sent to shareholders in preparation for the company's annual meeting or special meetings. It contains important information on matters that require a shareholder vote, typically including the election of the board of directors, various corporate actions, and other pertinent governance issues. The filing indicates that Vertex Pharmaceuticals is not required to pay a filing fee for this submission.

Vertex Pharmaceuticals Incorporated has filed a definitive proxy statement with the United States Securities and Exchange Commission (SEC). This filing is in accordance with Section 14(a) of the Securities Exchange Act of 1934. The proxy statement is a key document that is sent to shareholders in preparation for the company's annual meeting or special meetings. It contains important information on matters that require a shareholder vote, typically including the election of the board of directors, various corporate actions, and other pertinent governance issues. The filing indicates that Vertex Pharmaceuticals is not required to pay a filing fee for this submission.